And platinum medicine next-generation anti-CTLA-4 antibodies were approved clinically.

The HBM4003 is an all-human anti-CTLA-4 heavy-chain antibody that is produced from the unique Harbour Mice ® pharmaceuticals.
compared with traditional antibodies, heavy-chain antibodies (HCAb) consist of only two heavy chains, no light chains, their molecular weight is smaller than traditional antibodies, with better tissue penetration potential.
, heavy-chain antibodies have pharmacodynamic properties and immunoactivation (Fc) functions similar to IgG.
-chain antibodies bind to antigens only through heavy-chain variable regions, they can still show specificity similar to conventional antibodies.
HBM4003 shows enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), which is highly specific to CTLA-4High Treg cells in tumor tissue.
its powerful anti-tumor effects, differentiated pharmacodynamic characteristics and long-lasting llermic properties demonstrate good product characteristics, and this novel and differentiated mechanism of action has the potential to improve therapeutic effectiveness and significantly reduce drug toxicity.
HBM4003 Mechanisms for The Role of HBM4003 (Photo Source: and Platinum Pharmaceuticals Website) On February 28, 2020, HBM4003 was approved by the FDA for clinical trials of new drugs designed to assess the safety, toerability, pharmacodynamics, and anti-tumor activity of HBM4003.
addition, 2019 HBM4003 has been clinically phase 1 trial in Australia in 2019, and the first patient in the trial in November 2019 has successfully been successfully served and is now well under way.
it is understood that on August 18 this year, and Platinum Pharma submitted its main board listing application to the Hong Kong Stock Exchange, with Morgan Stanley, B of Securities and CITIC Securities acting as co-sponsors.
.